Alumis Inc.
NMS: ALMSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Alumis Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ALMS Z-Score →About Alumis Inc.
Healthcare
Biotechnology
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
📊 Fundamental Analysis
Alumis Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -86.7%, which indicates that capital utilization is currently under pressure.
At a current price of $23.05, ALMS currently sits at the 73rd percentile of its 52-week range (Range: $2.76 - $30.60).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
Key Financials
Market Cap
$2.93B
Trailing P/E
--
Forward P/E
-7.13
Beta (5Y)
--
52W High
$30.60
52W Low
$2.76
Avg Volume
1.62M
Day High
Day Low